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Background: The 24 mm Colibri TAVI valve is pre-mounted and compressed
upon its delivery balloon catheter at manufacture and is packaged ensheathed
within a 14 French introducer, sterilized and ready for insertion into the patient,
obviating typical valve rinsing, mounting and loading procedures. We report the
results of the COSTAS-I study of the ﬁrst-in-human cohort receiving the Colibri
Transcatheter Aortic Valve (CTAV) in an initial feasibility study at up to
18 months of follow-up.
Methods: The primary endpoints were successful valve implantation, valve perfor-
mance (gradient, area, jet velocity, regurgitation grade) and safety based on the
incidence of Major Adverse Cardiovascular and cerebrovascular events (MACCE) at
30 days. An initial cohort of 5 patients was enrolled. All patients were NYHA class
3-4, with preserved ejection fraction. The average aortic valve mean gradient (MG)
pre-procedure was 53 mmHg and the average aortic valve area (AVA) was 0.71 cm2.
Results: The valve was implanted successfully by transfemoral approach in all cases.
The mean MG decreased to 8.4 mmHg and mean AVA increased to 2.2 cm2. There
was no valvular regurgitation, no need for permanent pacemaker and no stroke. One
case had mild paravalvular insufﬁciency. All patients were discharged home ambu-
latory. Latest follow-up at 18 months, 10 months and three more at 6 months showed
no evidence of myocardial infarction, stroke, or kidney injury. There was no
requirement for permanent pacemaker or repeat procedures. All patients are
NYHA class 1. Most recent Echo-Doppler showed an average MG of 10 mmHg and
AVA of 2.2 cm2, no prosthetic valve insufﬁciency and only one patient with mild
paravalvular leak.
Conclusions: In this ﬁrst-in-human cohort, clinical outcome at up to 18 months after
implantation showed sustained beneﬁts. The COSTAS-I experience suggests that the
Colibri low proﬁle, ready-to-use TAVI technology is feasible and safe, can provide
procedural efﬁciencies and enable the transfemoral treatment of patients with small
femoral arteries. In a small cohort, a high AVA of 2.2 cm2 preserved over time
suggests that the valve design may minimize energy losses.
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Background: Prevalence of mixed aortic stenosis (MAS) in patients undergoing
TAVI is unclear. Due to the particular pathophysiology of this condition, these
patients could represent a high-risk group with regards to device malpositioning, post-
procedural aortic regurgitation (PPAR) and other complications. To date no study has
evaluated the performance of the commercially available Medtronic CoreValve
(MCV) and Edwards Sapien / SAPIEN XT (ESV) valve in this particular subgroup of
patients.
Methods: From November 2007 to September 2013 all patients with a documented
baseline MAS condition that underwent transfemoral (TF) TAVI either with MCV or
ESV, were included in this analysis. MAS patients were deﬁned by the presence of at
least moderate aortic stenosis (AS) associated with moderate or severe aortic regur-
gitation (AR). Outcomes were assessed according to valvular academic research
consortium (VARC-2) criteria at 30 days, 1 and 2 years.
Results: Among 472 patients in whom a baseline echocardiographic data were
available, 295 (62.4%) had a pure aortic stenosis (PAS) while 177 had MAS (37.6%).
Of 177 MAS patients, 59 (33.3%) were treated with MCV and 83 (46.8%) with ESV
through a TF approach. At 30 days there were no differences in all-cause mortality
(5.2% vs. 2.4%; p ¼ 0.391), cardiovascular mortality (3.4% vs 2.4%; p ¼ 0.724),
device success (58.6% vs. 67.5%; p ¼ 0.282) or early safety endpoint (34.5% vs.
25.3%; p ¼ 0.237). However, a greater incidence of valve embolization (7.5% vs. 0%;
p ¼ 0.013), need for a second valve (9.4% vs. 0%; p ¼ 0.005), permanent pacemaker
implantation (28.8% vs. 9.8%; p ¼ 0.010) and moderate to severe peri-prosthetic AR
(PPAR; 12.1% vs. 0%; p ¼ 0.001) was found in the MCV group. At 1 year there were
no differences in all-cause and cardiovascular mortality (15.5% vs. 12.2%; p ¼ 0.572,
and 12.1% vs. 4.9%; p ¼ 0.119). Finally, at 2 years, a greater all-cause (29.3% vs.
14.6%; p ¼ 0.035) and cardiovascular mortality (21.1% vs. 4.9%; p ¼ 0.001) was
found in the MCV group.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaConclusions: MCV was associated with a greater incidence of moderate-to-severe
PPAR and other intra- and peri-procedural complications in MAS patients that un-
derwent TAVI.
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Background: Signiﬁcant mitral regurgitation (MR) is present in 20-30% of patients
undergoing transcatheter aortic valve replacement (TAVR) and constitutes a signiﬁcant
co-existing valvular heart disease burden. We perform a meta-analysis and systematic
review of literature to evaluate the impact of signiﬁcant MR on outcomes after TAVR.
Methods: Eight studies comprising 8919 patients reporting TAVR outcomes based on
the presence or absence of moderate-severe MR were included. Risk ratios (RR) were
calculated using the inverse variance random effects model.
Results: None-mild MR was present in 77.8% and moderate-severe MR in 22.2% of
the patients. The presence of baseline moderate-severe MR, compared to none-mild
MR, was associated with increased mortality at 30-days (RR 1.24, 95% CI 1.13-1.37,
p < 0.00001) and 1 year (RR 1.21, 95% CI 1.10-1.34, p ¼ 0.0001; Figure 1A). The
increased mortality associated with moderate-severe MR was not inﬂuenced by the
etiology of MR (functional or degenerative MR) (RR 0.90, 95% CI 0.62-1.30,
p ¼ 0.56). The severity of MR improved in 61%  6.0% of patients after TAVR.
Moderate-severe residual MR, compared to none-mild residual MR post-TAVR, was
associated with signiﬁcantly increased 1-year mortality (RR 1.48, 95% CI 1.31-1.68,
p < 0.00001; Figure 1B).Conclusions: Baseline moderate-severe MR results in increased mortality after TAVR.
The severity of moderate-severe MR improves in the majority of patients undergoing
TAVR. Signiﬁcant residual MR post-TAVR is strongly associated with mortality; this
may represent an important group to target with transcatheter therapies in future.
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Background: While a certain degree of oversizing is required to reduce the incidence
of paravalvular leakage, prosthesis oversizing (PO) might be associated with increased
risk of conduction abnormalities leading to new pacemaker implantation. The aim of
this study was to assess the impact of valve oversizing on conduction abnormalitieslvular disease - Aortic: TAVR B207
